<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299765</url>
  </required_header>
  <id_info>
    <org_study_id>ISSIRES0109</org_study_id>
    <nct_id>NCT02299765</nct_id>
  </id_info>
  <brief_title>Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC</brief_title>
  <official_title>A Randomized, Open-label, Multiple-centre Study of Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced NSCLC With EGFR Mutation Positive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Title:

      Intercalating and maintenance Gefitinib in combination with chemotherapy (gemcitabine plus
      carboplatin) as first-line treatment for patients with advanced EGFR mutation-positive
      non-small cell lung cancer: A randomized, open-label, multiple-centre study.

      Target population-Treatment naive EGFR mutant-positive advanced NSCLC patients.

      Study Objectives - Primary Study Objective: To investigate whether intercalating and
      maintenance Gefitinib in combination with chemotherapy improve the Progression-Free Survival
      (PFS) vs. Gefitinib alone in advanced NSCLC with EGFR activating mutation.

      - Secondary Study Objective： To evaluate whether intercalating and maintenance Gefitinib in
      combination with chemotherapy improve the Objective Response Rate (ORR), Disease control rate
      (DCR), Overall survival (OS), 2-year OS rate, QOL vs. Gefitinib alone.

      Evaluation the safety of Intercalating and Maintenance Gefitinib in combination with
      chemotherapy.

      - Exploratory objective: PFS of arm A vs. PFS 1 + PFS 2 of arm B Dynamic biomarker analysis
      using blood sample

      a: The PFS 1 of arm B is the time from randomization to disease progression of 1st-line
      therapy or death from any cause, whichever occurs first. The PFS 2 of arm B is the time from
      the time of PFS 1 to disease progression of 2nd-line therapy or death from any cause,
      whichever occurs first.

      Study Design-Prospective, open-label, randomized, multi-center study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      It is a two-arm, prospective, randomized, open-label, multi-center study. The study will be
      conducted at 5 study sites in China. West China Hospital serves as the lead site for the
      study. A total of 146 treatments naive EGFR mutant positive advanced NSCLC patients are
      planned to be enrolled into this study.

      There are four periods in this study: baseline period (≤28days),main phase of treatment (Week
      0-Week 16 or until disease progression),post-treatment period and follow-up until about 24
      months after the last patients enrolment.

        1. Baseline period: Subject will be enrolled in the study after signing informed consent
           form (ICF). Investigator will record patient-reported outcome, demographic data and
           medical history, collect the histological or cytological samples for genetic testing,
           conduct laboratory examination and perform imaging examination and so on. Notes: The
           time of imagination is effective within 4 weeks before treatment. The result of
           haematology, biochemistry and physical examination is effective within 7 days before
           treatment. Collecting blood one time at screening period (The SOP of blood collection,
           storage and transportation is in attachment 1).

        2. Main phase of treatment: There are 8 visits during the main phase of treatment study.
           During the main phase of treatment, investigator conduct laboratory examination, perform
           imaging examination, assess the tumor status, and evaluate the patient-reported outcome
           and safety.

           Collecting blood one time every two cycles (The SOP of blood collection, storage and
           transportation is in attachment 1).

        3. Post-treatment period:

           In the study group, investigators will conduct laboratory examination, perform imaging
           examination, assess the tumor status, and evaluate the patient-reported outcome and
           safety until disease progression every 8 weeks. And after disease progression
           investigators will enquire and record survival status of subjects every 8 weeks.

           In the control group, investigators will conduct laboratory examination, perform imaging
           examination, assess the tumor status, and evaluate the patient-reported outcome and
           safety until the first and the second disease progression every 8 weeks. In addition,
           the information conduct between first disease progression and second progression are
           optional, but should be collected if available. And after the second disease progression
           investigators will enquire and record survival status of subjects every 8 weeks.

           Collecting blood one time every 8 weeks until progress (for control group it will be
           until the first progress)

        4. Follow-up period:

      It will last until about 24 months after the last patients' enrolment. Accesses histological
      or cytological samples for EGFR testing and related drug resistant gene testing are required.
      In addition, collection blood is optional, but should be collected if available. All the
      samples collected during his/her whole life treatment are transported to West China Hospital
      to store and will be used for further exploratory analysis later.

      All results of CT/MRI need to be burned into compact disc (CD). This study will be the first
      study to compare the efficacy of intercalating and maintenance gefitinib in combination with
      chemotherapy to gefitinib alone as first-line treatment for patients with advanced EGFR
      activating mutation-positive non-small cell lung cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the research data is not statistically significant
  </why_stopped>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival - PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to average 10 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate - ORR</measure>
    <time_frame>at day 42 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival - OS</measure>
    <time_frame>the time from randomization to death from any cause,assessed up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <condition>EGFR Activating Mutation</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four cycles gemcitabine(d1,8 ) + carboplatin (d1) + gefitinib (15-25), gefitinib 250mg/d from d15 of last cycle until disease progression.
Gemcitabine=1000mg/m2;Carboplatin 5×AUC ; One cycle is 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gefitinib 250mg/d until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>patients in arm A will be given gefitinib as target therapy</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>patients in arm A will be given gemcitabine chemotherapy</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Gemza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>patients in arm A will be given carboplatin chemotherapy</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Carboplatin Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects enrolled in this study are required to meet the following inclusion criteria:

               1. Patients between 18 and 75 years of age.

               2. Patients with histologically or cytologically diagnosed NSCLC,or patients with
                  recurrent advanced NSCLC after surgery.

               3. Harboring activating mutation of EGFR,only including an exon 19 deletion or an
                  exon 21 point mutation.

               4. Has at least one measureable lesion by RECIST 1.1

               5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

               6. No prior systemic chemotherapy or targeted therapy for lung cancer before
                  screening except neoadjuvant or adjuvant patients.

               7. Adequate organ function, including the following:

                  Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count
                  (ANC) ≥1.5 × 109/L,platelets ≥100 × 109/L,and hemoglobin ≥9 g/dL.

                  Hepatic: bilirubin ≤1.5 times the upper limit of normal (× ULN),alkaline
                  phosphatase (AP),aspartate transaminase (AST),and alanine transaminase (ALT) ≤3.0
                  × ULN (AP,AST and ALT ≤5 × ULN is acceptable if the liver has tumor involvement).

                  Renal: calculated creatinine clearance (CrCl) ≥45 mL/minute based on the standard
                  Cockcroft and Gault formula.

               8. Prior radiation therapy allowed to &lt;25% of the bone marrow. Prior radiation to
                  the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4
                  weeks before study enrolment.

               9. Signed informed consent document on file.

              10. Estimated life expectancy of ≥12 weeks.

              11. Patient compliance and geographic proximity that allow adequate follow up.

                  Exclusion Criteria:

          -  Subjects meeting any of the following exclusion criteria are not to be enrolled in the
             study.

               1. Known severe hypersensitivity to gefitinib.

               2. Known brain metastasis unless asymptomatic brain metastasis(without neurotic
                  symptoms and sign) and treated with surgery and/or radiation and stable without
                  steroid treatment for at least 2 weeks prior to the first dose of study
                  medication.

               3. Pleural effusion or pericardiac effusion that cannot be controlled by drainage or
                  other procedures.

               4. Previous treatment with agents targeting the HER axis.

               5. Previous systemic antitumour treatment.

               6. The last regimen of neoadjuvant or adjuvant treatment for non-metastatic disease
                  within 12 months of study treatment.

               7. EGFR Resistance mutation (+).

               8. Surgery undertaken less than 4 weeks before the study.

               9. Inability to comply with protocol or study procedures.

              10. A serious concomitant systemic disorder that,in the opinion of the
                  investigator，would compromise the patient's ability to complete the study.

              11. A serious cardiac condition,such as myocardial infarction within 6
                  months,angina,or heart disease.

              12. Second primary malignancy that is clinically detectable at the time of
                  consideration for study enrolment.

              13. Past medical history of Interstitial Lung Disease(ILD),drug induced interstitial
                  disease,radiation pneumonitis which required steroid treatment,or any evidence of
                  clinically active ILD.

              14. Pre-existing idiopathic pulmonary fibrosis evidence by CT scan at baseline.

              15. Unwillingness to use contraception during the study, women who were pregnant or
                  lactating.

              16. Being or planing to participate in other studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>You Lu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Thoracic Oncology, Cancer center, West China Hospital, Sichuan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China West Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.</citation>
    <PMID>19692680</PMID>
  </reference>
  <reference>
    <citation>Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27.</citation>
    <PMID>22370314</PMID>
  </reference>
  <reference>
    <citation>Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004 Mar 1;22(5):777-84.</citation>
    <PMID>14990632</PMID>
  </reference>
  <reference>
    <citation>Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004 Mar 1;22(5):785-94.</citation>
    <PMID>14990633</PMID>
  </reference>
  <reference>
    <citation>Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 1;23(25):5892-9. Epub 2005 Jul 25.</citation>
    <PMID>16043829</PMID>
  </reference>
  <reference>
    <citation>Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007 Apr 20;25(12):1545-52.</citation>
    <PMID>17442998</PMID>
  </reference>
  <reference>
    <citation>Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 2007 Jun 1;13(11):3413-22.</citation>
    <PMID>17545550</PMID>
  </reference>
  <reference>
    <citation>Cheng H, An SJ, Zhang XC, Dong S, Zhang YF, Chen ZH, Chen HJ, Guo AL, Lin QX, Wu YL. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemother Pharmacol. 2011 Mar;67(3):637-46. doi: 10.1007/s00280-010-1347-4. Epub 2010 May 22.</citation>
    <PMID>20495920</PMID>
  </reference>
  <reference>
    <citation>Piperdi B, Ling Y-H, Kroog G, et al. Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/Mb) on human NSCLC cell lines in vitro [J]. J Clin Oncol, 2004; 22: 7028.</citation>
  </reference>
  <reference>
    <citation>Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205. Erratum in: N Engl J Med. 2012 Sep 6;367(10):976.</citation>
    <PMID>22397650</PMID>
  </reference>
  <reference>
    <citation>Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86. doi: 10.1016/S1470-2045(13)70254-7. Epub 2013 Jun 17.</citation>
    <PMID>23782814</PMID>
  </reference>
  <reference>
    <citation>Yoshimura1 N, Matsuura1 K, Mitsuoka1 S, et al. Gefitinib(G) and pemetrexed（PEM）as a first line treatment in patients with EGFR mutation advanced non-small-cell cancer(NSCLC): a phase II study. ESMO 2012,1258p.</citation>
  </reference>
  <reference>
    <citation>Kanda S, Ohe Y, Horinouchi H, et al. Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer harboring an epidermal growth factor receptor activating mutation. ASCO Abstract, 2013,8064.</citation>
  </reference>
  <reference>
    <citation>Choi YJ, Kim SW, Lee DH, et al.Paclitaxel/carboplatin (PC) intercalated with gefitinib or paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC) in selected population who were smoker or wild-type EGFR: Randomized phase II study. ASCO Abstract, 2013, e19079.</citation>
  </reference>
  <reference>
    <citation>Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.</citation>
    <PMID>20493771</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012 May;13(5):466-75. doi: 10.1016/S1470-2045(12)70117-1. Epub 2012 Apr 17.</citation>
    <PMID>22512843</PMID>
  </reference>
  <reference>
    <citation>Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011 Mar 10;364(10):947-55. doi: 10.1056/NEJMct0807960. Review.</citation>
    <PMID>21388312</PMID>
  </reference>
  <reference>
    <citation>Kuo LC, Lin PC, Wang KF, Yuan MK, Chang SC. Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Med Oncol. 2011 Mar;28(1):79-82. doi: 10.1007/s12032-010-9424-4. Epub 2010 Jan 20. Review.</citation>
    <PMID>20087691</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>November 23, 2017</last_update_submitted>
  <last_update_submitted_qc>November 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>You Lu</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Advanced Non-small Cell Lung Cancer (NSCLC)</keyword>
  <keyword>EGFR Mutation</keyword>
  <keyword>gefitinib</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

